AzTrials
AzTrials

SepsisNCT00844337

Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh

A study testing Gentamicin & Amoxicillin x 7days, Penicillin & gentamicin x 2 d + Amoxicillin X 5 d and Standard reference therapy in people with Sepsis, run by Johns Hopkins Bloomberg School of Public Health at 3 sites in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary aim is to establish the non-inferiority of several simplified, home-based antibiotic regimens compared to the standard course of parenteral antibiotics for the empiric treatment of suspected sepsis in Bangladeshi young infants whose parents refuse hospitalization. Read more about this study

Who is it for?
Ages Up to 59 days
Conditions the study is for
Sepsis
What is being tested?
Gentamicin & Amoxicillin x 7days, Penicillin & gentamicin x 2 d + Amoxicillin X 5 d and Standard reference therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,490 participants
Where
3 sitesBangladesh
Study dates
Mar 2009to Sep 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 59 days
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Infants 0-59 days old who are residents of catchment population of the study hospitals
  • One or more of the following five signs: severe chest in-drawing, axillary temperature >37.80C or <35.50 C, lethargic or less than normal movement, and history of feeding problems (confirmed by poor suck on feeding assessment)
  • Family refuses recommended hospitalization or hospitalization otherwise not feasible
  • Informed consent by a legal guardian.

Who cannot join

  • Very severe infection/disease characterized by presence of any of the following signs (unconscious, convulsions, unable to feed, apnea, unable to cry, cyanosis, bulging fontanel, major congenital malformations, major bleeding, surgical conditions needing hospital referral, persistent vomiting defined as vomiting following three attempts to feed the baby within ½ hour, and/or physician's suspicion of meningitis)
  • Very low birth weight: weight <1500
  • Hospitalization for illness in the last two weeks
  • Hospital born infants
  • Previous inclusion in the study

Trial locations and contacts

3 sites in 1 country.

Bangladesh3 sites
  • Chittagong Ma O Shishu Hospital

    Chittagong

  • Dhaka Shishu Hospital/CHRF

    Dhaka, Dhaka Division, 1216

  • Shishu Shastya Foundation

    Dhaka

Other trials in Bangladesh

About this study

Official title: Safety and Efficacy of Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh

The primary aim is to establish the non-inferiority of several simplified, home-based antibiotic regimens compared to the standard course of parenteral antibiotics for the empiric treatment of suspected sepsis in Bangladeshi young infants whose parents refuse hospitalization. Three alternative regimens will be compared with a standard (reference) regimen of injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. Alternative regimens are (1) injectable gentamicin once daily and oral amoxicillin twice daily for seven days; (2) injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days; and (3) injectable gentamicin once daily and oral amoxicillin twice daily for two days followed by oral amoxicillin twice daily for five days.

Hypothesis

Read more

The proportion who fails treatment will be 10 percent in the reference group and the alternative treatment groups. An alternative therapy will be considered non-inferior to the standard therapy if the failure rate in the alternative therapy exceeds the failure rate in the injectable therapy by less than 5 absolute percentage points.

Secondary Objectives:

  • To identify baseline clinical predictors of treatment failure in severe infections in young infants.
  • To determine the proportion of relapse (young infants who were considered cured by day 7 but developed any of the signs of suspected severe infection by day 14).
Read the detailed description

Although many developing countries have witnessed declines in both post-neonatal and 1-4 year-old child deaths, neonatal death rates have remained relatively constant, with an estimated 4 million annual neonatal deaths globally (Lawn et al, 2005). Almost all of the neonatal deaths (99%) occur in developing countries (Bryce et al., 2005; Ahmad et al., 2007). In many of these settings, the rate of home delivery is high and the attendance at birth by skilled personnel is low, leading to many babies being born in unhygienic conditions (Bhutta et al., 2005). Birth in these settings is accompanied by a high rate of infections in both mothers and newborns. It has been estimated that about 1 out of 5 neonates develop life threatening infections (Stoll, 1997). Several preventative interventions against neonatal infections including tetanus toxoid immunization to pregnant women, early and exclusive breastfeeding, and use of clean delivery kits have been identified and incorporated in many programs (Bhutta et al., 2005). Yet, neonatal infections remain the most important cause of neonatal deaths. Globally, an estimated one-third of the neonatal deaths are attributed to infections (Lawn 2005). In settings characterized by high neonatal mortality rates, the proportion of neonatal deaths due to infections has been estimated at approximately 50% (Bang 1999; Lawn 2005; Baqui 2006). These infectious deaths include sepsis, pneumonia, tetanus, meningitis and diarrhea. A further 27% of the neonatal deaths are related to premature birth and infections are the direct cause in many of these premature neonates. Therefore, strategies for timely identification and management of infections in young infants (0-59 days) including neonates are urgently needed.

Current Treatment Options: Hospital care The WHO recommends that all cases of suspected severe infection in young infants (0-59 days old) are treated in hospitals with a 7-10 day course of injectable antibiotics - penicillin (or ampicillin) and gentamicin. However, in many developing countries, this care is often not available or accessible, or not acceptable to families. Furthermore, in low-resource settings, reliance on a strategy of hospitalization of young infants with suspected severe infections has a number of inherent disadvantages. First, in many settings, a vast majority of young infants who are referred may not be able to get to the hospital (Peterson et al., 2004) and may not receive the treatment, increasing their risk of dying. Second, routine hospitalization and the use of injectable antibiotics, either intravenously or intramuscularly substantially increases the cost of health care (Al-Eidan et al., 1999) and often hospital beds are not available to admit all young infants with suspected serious infections. Third, hospitalization increases the risk of exposure to multi-drug resistant nosocomial pathogens that are increasingly difficult to treat (Jarvis WR, 2004; Pong et al., 2004).

Evidence of alternative approaches:

Strategies for community-based management of infections in young infants have been developed and evaluated in several research settings (Bang et al., 1999; Baqui et al., 2007; Kanal et al., 2007). Our group, known as Projahnmo, has recently completed a trial of a package of maternal and neonatal interventions in Sylhet district, Bangladesh, and demonstrated significant reduction of neonatal mortality (Baqui et al., 2008b). In one of the intervention arms, we trained village-based community health workers to assess newborns and manage newborns with severe infections using an algorithm similar to the one used in Integrated Management of Childhood and Neonatal Illness (IMNCI). Management included referral of neonates with signs of severe infection to a qualified provider and home treatment in referral failure cases. If referral failed but parents consented to home treatment, CHWs treated neonates with severe infections using injectable procaine penicillin and gentamicin. For severe infections, the rate of referral compliance was only 34%, and home treatment acceptance was 43%. The case fatality rate was 4.4% for those treated by CHWs, 14.2% for those treated by qualified medical providers, and 28.5% for those who either received no treatment or who were treated by untrained providers. After controlling for differences in background characteristics and illness signs among treatment groups, newborns treated by CHWs had a hazard ratio of 0.22 (95% confidence interval 0.07-0.71) for death during neonatal period and those treated by qualified providers had a hazards ratio of 0.60 (95% confidence interval of 0.37-0.99), compared to newborns who received no treatment or were treated by untrained providers (Baqui et al., 2007; Baqui et al., 2008a). These data suggest that treatment of neonates by CHWs was generally acceptable to the community. Home treatment of suspected sepsis in neonates by CHWs is effective in low-resource settings.

There are, however, major challenges associated with current community-based strategies for injectable therapy. First, it is difficult to ensure availability of trained health workers who are able to safely and optimally administer injectable antibiotics daily for 7 to 10 days, and to ensure supplies and quality assurance. Second, a 7 to 10-day regimen of parenteral antibiotic therapy presents specific challenges to community acceptance and compliance. Third, unsupervised use of injection at the community level may be unsafe and can increase the risk of transmission of HIV, hepatitis and other viral diseases through the use of contaminated needles (Simonsen et al., 1999). Therefore, it is important to reduce the number of injections to be used in the community. Furthermore, the rationale for 7-10 days of parenteral antibiotic therapy is not fully established. Injectable therapy is chosen because of the perception that it is the most efficacious regimen in the treatment of severe disease. For some neonatal infections, however, alternative regimes such as a combination of parenteral and oral therapy or switching to an oral antibiotic after initial treatment for 2-3 days with injectable antibiotics may be equally effective.

To overcome the disadvantages of hospitalization and challenges of community-based injectable therapy, recent research has looked at the potential use of oral treatment for severe pneumonia in older infants. Hazir et al (2008) recently reported the results from an open-label equivalency trial conducted at seven study sites in Pakistan. 2,037 children aged 3-59 months with severe pneumonia were randomly allocated to either initial hospitalization and parenteral ampicillin (100 mg/kg per day in four doses) for 48 h, followed by 3 days of oral amoxicillin (80-90 mg/kg per day in two doses; n=1012) or to home-based treatment for 5 days with oral amoxicillin (80-90 mg/kg per day in two doses; n=1025). Follow-up assessments were done at days 1, 3, 6, and 14 after enrolment. There was no difference in treatment failure rates (clinical deterioration) by day 7 between the hospitalized (8.6%) and the ambulatory group (7.5%; risk difference 1•1%; 95% CI -1•3 to 3•5). This result suggests empowering first-level health workers to manage severely ill children when referral is difficult. High failure rates were associated with young age, very fast breathing, and low weight for age. These findings suggest that it may not be safe to treat young infants with suspected severe infection with oral antibiotic alone.

Global research priority: Simplified antibiotic regimen for infections in young infants

In the fall of 2007, Saving Newborn Lives (SNL) of Save the Children-US, USAID and WHO convened a global consultation to review the new study findings on infection management in young infants in community-based settings and to guide future research priorities. Based on the existing research findings at that time, the consultation participants concluded that there was still insufficient evidence to make policy recommendations for global programs. The consultation charged future research to test optimal combination of oral and intramuscular (IM) antibiotic regimens that would be feasible to implement in first-level facilities and community and will be acceptable to families for settings characterized by weak health systems. We designed this study with these recommendations in mind.

Conditions
Sepsis
Being tested
Gentamicin & Amoxicillin x 7days, Penicillin & gentamicin x 2 d + Amoxicillin X 5 d, Standard reference therapy
Keywords
antibiotic regimens, sepsis, young infants, Bangladeshi, outpatient treatment, Suspected sepsis in young infants
Medical subject headings
Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gentamicin & Amoxicillin x 7daysDrug

    Also called Gentamicin & Amoxicillin

    Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.

    The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day.

  • Penicillin & gentamicin x 2 d + Amoxicillin X 5 dDrug

    Also called Penicillin, Gentamicin

    Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.

  • Standard reference therapyDrug

    Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.

Study groups in NCT00844337
Study groupRoleWhat they receive
1Active comparatorOne study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
Receives: Drug: Gentamicin & Amoxicillin x 7days
2Active comparatorInjectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
Receives: Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d
3Active comparatorInjectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
Receives: Drug: Standard reference therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment failure

    Measured: Seven days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Feb 2009 (estimated)
  2. Study startMar 2009
  3. Primary completionSep 2013
  4. Study completionSep 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
2,490 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00844337
Sponsor's protocol ID
JHU IRB 1440
Other IDs
USAID GHS-A-00-09-00004-00
Status last verified
Sep 2014
First submitted
13 Feb 2009
Last updated
16 Sep 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Longombe AL, Ayede AI, Marete I, Mir F, Ejembi CL, Shahidullah M, Adejuyigbe EA, Wammanda RD, Tshefu A, Esamai F, Zaidi AK, Baqui AH, Cousens S. Oral amoxicillin plus gentamicin regimens may be superior to the procaine-penicillin plus gentamicin regimens for treatment of young infants with possible serious bacterial infection when referral is not feasible: Pooled analysis from three trials in Africa and Asia. J Glob Health. 2022 Nov 21;12:04084. doi: 10.7189/jogh.12.04084.

    PubMed 36403158
  • Baqui AH, Saha SK, Ahmed AS, Shahidullah M, Quasem I, Roth DE, Samsuzzaman AK, Ahmed W, Tabib SM, Mitra DK, Begum N, Islam M, Mahmud A, Rahman MH, Moin MI, Mullany LC, Cousens S, El Arifeen S, Wall S, Brandes N, Santosham M, Black RE; Projahnmo Study Group in Bangladesh. Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet Glob Health. 2015 May;3(5):e279-87. doi: 10.1016/S2214-109X(14)70347-X. Epub 2015 Apr 1.

    PubMed 25841891
  • Baqui AH, Saha SK, Ahmed AS, Shahidullah M, Quasem I, Roth DE, Williams EK, Mitra D, Shamsuzzaman AK, Ahmed W, Mullany LC, Cousens S, Wall S, Brandes N, Black RE. Safety and efficacy of simplified antibiotic regimens for outpatient treatment of serious infection in neonates and young infants 0-59 days of age in Bangladesh: design of a randomized controlled trial. Pediatr Infect Dis J. 2013 Sep;32 Suppl 1(Suppl 1 Innovative Treatment Regimens for Severe Infections in Young Infants):S12-8. doi: 10.1097/INF.0b013e31829ff790.

    PubMed 23945570

Questions about this trial

What is this clinical trial studying?

A study testing Gentamicin & Amoxicillin x 7days, Penicillin & gentamicin x 2 d + Amoxicillin X 5 d and Standard reference therapy in people with Sepsis, run by Johns Hopkins Bloomberg School of Public Health at 3 sites in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment failure (time frame: Seven days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00844337, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in